JPMorgan analyst Gary Taylor lowered his price target for DaVita HealthCare Partners to $65 after the Centers for Medicare & Medicaid Services said it is examining inappropriate steering of people eligible for Medicare or Medicaid into Marketplace plans. Taylor believes exchange health plans may reject the majority of American Kidney Fund dialysis third party premium assistance payments during 2017 open enrollment this Fall. This threatens at least 1% of DaVita's patient mix, the analyst tells investors in a research note. He keeps a Neutral rating on the shares.